Acromegaly is typically caused by a growth hormone–secreting pituitary adenoma, driving
excess secretion of insulin-like growth factor 1. Acromegaly may result in a variety of …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Acromegaly is a rare disorder caused by chronic growth hormone (GH) hypersecretion.
While diagnostic and therapeutic methods have advanced, little information exists on trends …

Context Silent pituitary adenomas are anterior pituitary tumors with hormone synthesis but
without signs or symptoms of hormone hypersecretion. They have been increasingly …

Pituitary adenomas are one of the most frequent intracranial tumors and occur with a
prevalence of approximately 1: 1000 in the developed world. Pituitary adenomas have a …

Pituitary adenomas may hypersecrete hormones (including prolactin, growth hormone and
adrenocorticotropic hormone, and rarely follicle-stimulating hormone, luteinizing hormone or …

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs
in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and …

X-linked acrogigantism (X-LAG) is a new syndrome of pituitary gigantism, caused by
microduplications on chromosome Xq26. 3, encompassing the gene GPR101, which is …

Acromegaly is associated with high morbidity and elevated mortality when not adequately
treated. Surgery is the first-line treatment for most patients as it is the only one that can lead …

Acromegaly is a chronic disease with increased morbidity and mortality, where usually
multiple treatment modalities are used. The somatostatin analogs (SSAs) are the mainstay of …